BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Natsuaki M, Morimoto T, Yamamoto E, Shiomi H, Furukawa Y, Abe M, Nakao K, Ishikawa T, Kawai K, Yunoki K, Shimizu S, Akao M, Miki S, Yamamoto M, Okada H, Hoshino K, Kadota K, Morino Y, Igarashi K, Tanabe K, Kozuma K, Kimura T. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial. Cardiovasc Interv Ther 2016;31:196-209. [PMID: 26518420 DOI: 10.1007/s12928-015-0366-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Arahata M, Asakura H. Antithrombotic therapies for elderly patients: handling problems originating from their comorbidities. Clin Interv Aging 2018;13:1675-90. [PMID: 30237704 DOI: 10.2147/CIA.S174896] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
2 Migita S, Kitano D, Li Y, Koyama Y, Shimodai-Yamada S, Onishi A, Fuchimoto D, Suzuki S, Nakamura Y, Matsuyama TA, Hirota S, Sakuma M, Tsujimoto M, Hirayama A, Okumura Y, Hao H. Pathological findings after third- and second-generation everolimus-eluting stent implantations in coronary arteries from autopsy cases and an atherosclerotic porcine model. Sci Rep 2021;11:6281. [PMID: 33737695 DOI: 10.1038/s41598-021-85740-2] [Reference Citation Analysis]
3 Yamashita Y, Shiomi H, Morimoto T, Yaku H, Furukawa Y, Nakagawa Y, Ando K, Kadota K, Abe M, Nagao K, Shizuta S, Ono K, Kimura T. Cardiac and Noncardiac Causes of Long-Term Mortality in ST-Segment–Elevation Acute Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention. Circ: Cardiovascular Quality and Outcomes 2017;10. [DOI: 10.1161/circoutcomes.116.002790] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 6.3] [Reference Citation Analysis]
4 Yoshikawa S, Ashikaga T, Miyazaki T, Kurihara K, Hirao K. Long-Term Efficacy and Safety of Everolimus-Eluting Stent Implantation in Japanese Patients with Acute Coronary Syndrome: Five-Year Real-World Data from the Tokyo-MD PCI Study. J Interv Cardiol 2019;2019:3146848. [PMID: 31777468 DOI: 10.1155/2019/3146848] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Horie K, Matsumoto T, Mizutani Y, Tada N, Osai N, Isawa T, Taguri M, Kato S, Honda T, Ootomo T, Inoue N. A prospective interventional registry of short-term dual-antiplatelet treatment after implantation of drug-eluting stents in patients with atrial fibrillation requiring oral anticoagulation therapy. Cardiovasc Interv Ther 2020;35:150-61. [PMID: 31093885 DOI: 10.1007/s12928-019-00589-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Konishi A, Iwasaki M, Shinke T, Otake H, Takaya T, Osue T, Nishio R, Kinutani H, Kuroda M, Takahashi H, Terashita D, Shite J, Hirata KI. Favorable early vessel healing after everolimus-eluting stent implantation: 3-, 6-, and 12-month follow-up of optical coherence tomography. J Cardiol 2018;72:193-9. [PMID: 29980334 DOI: 10.1016/j.jjcc.2018.04.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
7 Ueshima D, Ashikaga T, Yoshikawa S, Sasaoka T, Hatano Y, Kurihara K, Maejima Y, Isobe M. Effect of over-2-year dual antiplatelet therapy on the rate of major adverse cardiac and cerebral events for everolimus-eluting stent implantation: The landmark analysis from Tokyo-MD PCI registry. Journal of Cardiology 2017;69:815-22. [DOI: 10.1016/j.jjcc.2016.08.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Kadota K, Ando K, Shiomi H, Toyota T, Watanabe H, Ono K, Shizuta S, Tamura T, Inoko M, Inada T, Shirotani M, Matsuda M, Aoyama T, Onodera T, Suwa S, Takeda T, Inoue K, Kimura T; CREDO-Kyoto PCI/CABG registry cohort-2 investigators. Short versus prolonged dual antiplatelet therapy duration after bare-metal stent implantation: 2-month landmark analysis from the CREDO-Kyoto registry cohort-2. Cardiovasc Interv Ther 2018;33:23-34. [PMID: 27646646 DOI: 10.1007/s12928-016-0429-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Ishida M, Takahashi F, Goto I, Niiyama M, Saitoh H, Sakamoto T, Maegawa Y, Osaki T, Nishiyama O, Endo H, Sakamoto R, Kojima T, Koeda Y, Kimura T, Itoh T, Morino Y; REIWA investigators. Clinical outcomes of patients treated using very short duration dual antiplatelet therapy after implantation of biodegradable-polymer drug-eluting stents: rationale and design of a prospective multicenter REIWA registry. Cardiovasc Interv Ther 2020;35:398-404. [PMID: 32776221 DOI: 10.1007/s12928-020-00694-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Natsuaki M, Morimoto T, Yamamoto E, Watanabe H, Furukawa Y, Abe M, Nakao K, Ishikawa T, Kawai K, Yunoki K, Shimizu S, Akao M, Miki S, Yamamoto M, Okada H, Hoshino K, Kadota K, Morino Y, Hanaoka KI, Tanabe K, Kozuma K, Kimura T; STOPDAPT trial investigators. One-year clinical outcomes of patients with versus without acute coronary syndrome with 3-month duration of dual antiplatelet therapy after everolimus-eluting stent implantation. PLoS One 2020;15:e0227612. [PMID: 32210433 DOI: 10.1371/journal.pone.0227612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Sato T, Taya Y, Suzuki N, Yuasa S, Kishi S, Koshikawa T, Fuse K, Fujita S, Ikeda Y, Kitazawa H, Takahashi M, Okabe M, Aizawa Y. The comparison of early healing 1-month after PCI among CoCr-everolimus-eluting stent (EES), biodegradable polymer (BP)-EES and BP-sirolimus-eluting stent: Insights from OFDI and coronary angioscopy. Int J Cardiol Heart Vasc 2018;20:40-5. [PMID: 30167453 DOI: 10.1016/j.ijcha.2018.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Ozaki Y, Katagiri Y, Onuma Y, Amano T, Muramatsu T, Kozuma K, Otsuji S, Ueno T, Shiode N, Kawai K, Tanaka N, Ueda K, Akasaka T, Hanaoka KI, Uemura S, Oda H, Katahira Y, Kadota K, Kyo E, Sato K, Sato T, Shite J, Nakao K, Nishino M, Hikichi Y, Honye J, Matsubara T, Mizuno S, Muramatsu T, Inohara T, Kohsaka S, Michishita I, Yokoi H, Serruys PW, Ikari Y, Nakamura M; Task Force on Primary Percutaneous Coronary Intervention (PCI) of the Japanese Cardiovascular Interventional Therapeutics (CVIT). CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) in 2018. Cardiovasc Interv Ther 2018;33:178-203. [PMID: 29594964 DOI: 10.1007/s12928-018-0516-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 27] [Article Influence: 16.7] [Reference Citation Analysis]
13 Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, Ohya M, Suwa S, Takagi K, Nanasato M, Hata Y, Yagi M, Suematsu N, Yokomatsu T, Takamisawa I, Doi M, Noda T, Okayama H, Seino Y, Tada T, Sakamoto H, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Hanaoka KI, Morino Y, Kozuma K, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; STOPDAPT-2 Investigators. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA 2019;321:2414-27. [PMID: 31237644 DOI: 10.1001/jama.2019.8145] [Cited by in Crossref: 279] [Cited by in F6Publishing: 181] [Article Influence: 139.5] [Reference Citation Analysis]
14 Goli RR, Contractor MM, Nathan A, Tuteja S, Kobayashi T, Giri J. Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications. Curr Atheroscler Rep 2017;19. [DOI: 10.1007/s11883-017-0698-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Hahn J, Song YB, Oh J, Cho D, Lee JB, Doh J, Kim S, Jeong J, Bae J, Kim B, Cho JH, Suh I, Kim D, Park H, Park J, Choi WG, Lee WS, Kim J, Choi KH, Park TK, Lee JM, Yang JH, Choi J, Choi S, Gwon H, Gwon H, Hahn J, Song YB, Park TK, Lee JM, Yang JH, Choi J, Choi S, Lee J, Choi WG, Bae J, Park HS, Hwang J, Hur S, Rha S, Cho D, Cho SC, Kang WY, Lim S, Lee JB, Kim MH, Cha KS, Choi RK, Chae I, Oh J, Jang WJ, Park YH, Chun WJ, Kim S, Cho JH, Suh I, Park J, Choi JW, Kim B, Doh J, Kim D, Jeong MH, Kang SH, Lee WS, Park H, Jeong J, Ahn K. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. The Lancet 2018;391:1274-84. [DOI: 10.1016/s0140-6736(18)30493-8] [Cited by in Crossref: 135] [Cited by in F6Publishing: 40] [Article Influence: 45.0] [Reference Citation Analysis]
16 Kitabata H, Kubo T, Mori K, Yamamoto Y, Kashiwagi M, Arita Y, Tanimoto T, Akasaka T. Safety and efficacy outcomes of second-generation everolimus-eluting stents in octogenarians compared to non-octogenarians. Cardiovascular Revascularization Medicine 2018;19:12-6. [DOI: 10.1016/j.carrev.2017.05.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Mori H, Jinnouchi H, Diljon C, Torii S, Sakamoto A, Kolodgie FD, Virmani R, Finn AV. A new category stent with novel polyphosphazene surface modification. Future Cardiology 2018;14:225-35. [DOI: 10.2217/fca-2017-0103] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]